phrykt

Nektar Therapeutics (NKTR): who owns it and who trades it

As of Nov 16, 2026, NKTR insiders reported 16 open-market sales worth $2.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Howard W Robin (CEO), with $1.4M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Nektar Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NKTR

239 funds and institutions reported NKTR shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 17.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)17.7%
Two Seas Capital LP10.8%
BlackRock, Inc.10.3%
Bvf Inc8.3%
Vanguard Capital Management LLC5.2%
Two Sigma Investments, LP4.2%
Vestal Point Capital, LP3.5%
Morgan Stanley3.3%
State Street Corp3.2%
Geode Capital Management, LLC3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)5.07M17.67%$354M+18%
Two Seas Capital LP3.09M10.78%$216M+58%
BlackRock, Inc.2.94M10.25%$205M+325%
Bvf Inc2.39M8.33%$167M-7%
Vanguard Capital Management LLC1.50M5.22%$104M+25%
Two Sigma Investments, LP1.20M4.19%$83.9M+29%
Vestal Point Capital, LP1.00M3.49%$69.8M+251%
Morgan Stanley936,5603.26%$65.4M+42%
State Street Corp909,6793.17%$63.5M+272%
Geode Capital Management, LLC881,3063.07%$61.5M+154%
Prosight Management, LP810,0002.82%$56.5M+10%
Armistice Capital, LLC724,0002.52%$50.5M+25%
Gilder Gagnon Howe & Co LLC600,8732.09%$41.9M+121%
Millennium Management LLC478,1201.67%$33.4M+18%
Braidwell LP473,6171.65%$33.1M+113%
Sofinnova Investments, Inc.471,7631.64%$32.9M-7%
Woodline Partners LP470,8751.64%$32.9M+13%
Orbimed Advisors LLC465,3461.62%$32.5M+69%
UBS Group AG428,4001.49%$29.9M+34%
Emerald Advisers, LLC390,1581.36%$27.2M-1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NKTR insiders reported $0 of open-market purchases and $2.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.4M
16 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 18, 2026
Filed Aug 20, 2026

Purchases and sales by month

$1.9M$1.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 18, 2026Jonathan ZalevskyChief R&D OfficerSale186$71.98$13.4KForm 4
Aug 18, 2026Howard W RobinCEOSale418$71.98$30.1KForm 4
Jun 30, 2026Jonathan ZalevskyChief R&D OfficerSale5,681$70.00$398KForm 4
Jun 17, 2026Howard W RobinCEOSale5,500$60.81$334KForm 4
Jun 17, 2026Howard W RobinCEOSale4,500$61.65$277KForm 4
Jun 16, 2026Howard W RobinCEOSale5,303$59.97$318KForm 4
Jun 16, 2026Howard W RobinCEOSale4,697$60.71$285KForm 4
Jun 15, 2026Jonathan ZalevskyChief R&D OfficerSale5,538$60.71$336KForm 4
May 19, 2026Jonathan ZalevskyChief R&D OfficerSale199$65.51$13KForm 4
May 19, 2026Howard W RobinCEOSale444$65.51$29.1KForm 4
Feb 18, 2026Jonathan ZalevskyChief R&D OfficerSale180$73.00$13.1KForm 4
Feb 18, 2026Howard W RobinCEOSale423$73.00$30.9KForm 4
Jan 20, 2026Jonathan ZalevskyChief R&D OfficerSale3,867$35.67$138KForm 4
Nov 25, 2025Jonathan ZalevskyChief R&D OfficerSale1,157$54.28$62.8KForm 4
Nov 25, 2025Mark Andrew WilsonChief Legal OfficerSale630$54.28$34.2KForm 4
Nov 25, 2025Howard W RobinCEOSale2,207$54.28$120KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Howard W RobinPresident & CEO, Director–$1.4MAug 18, 2026
Jonathan ZalevskyChief R&D Officer–$974KAug 18, 2026
Mark Andrew WilsonChief Legal Officer–$34.2KNov 25, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NKTR short interest

High short interest. 19.8% of NKTR shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 55%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.77M NKTR shares were sold short, 19.8% of the shares outstanding, down 3.3% from the report before. At the average daily volume of 659,707 shares, buying them all back would take about 10.3 trading days (days to cover).

Shares short, % of all shares

19.8%May 15Oct 3025.4%

Days to cover

10.3May 15Oct 3012.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.77M19.82%-3%659,70710.3
Oct 15, 20267.00M20.50%+0%1.99M3.5
Sep 30, 20266.97M20.41%+21%1.85M3.8
Sep 15, 20265.74M16.80%-5%757,1947.6
Aug 31, 20266.07M17.77%-2%530,09411.4
Aug 14, 20266.17M18.07%-2%591,70210.4
Jul 31, 20266.30M21.97%-8%731,3338.6
Jul 15, 20266.82M23.77%-1%978,2417.0
Jun 30, 20266.90M24.04%+39%1.54M4.5
Jun 15, 20264.94M17.23%+7%1.00M4.9
May 29, 20264.61M16.08%+6%867,9715.3
May 15, 20264.37M15.23%+6%838,2455.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Nektar Therapeutics company events

Nektar Therapeutics filed 17 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 1, 2026.

  1. Oct 1, 2026AnnouncementShared information with investors. Filing
  2. Sep 25, 2026AnnouncementIn August 2023, Nektar Therapeutics filed a complaint in the U.S. District Court for the Northern District of California against Eli Lilly and Company alleging, among other claims, breach of contract and breach of the implied covenant of good faith and fair dealing in connection with the license… Filing
  3. Sep 8, 2026AnnouncementShared information with investors. Filing
  4. Aug 13, 2026ResultsReleased financial results. Filing
  5. Jun 5, 2026VoteReported shareholder vote results. Filing
  6. May 8, 2026LeadershipThe Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 23, 2026AgreementNektar Therapeutics entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. as the representatives of the several underwriters named therein, relating to an underwritten offering of 3,532,609 shares of the Company’s common stock, $0.0001 par value… Filing
  9. Apr 20, 2026AnnouncementShared information with investors. Filing
  10. Apr 20, 2026AnnouncementThe Company announced 52-week topline results from the blinded 16-week treatment extension period of its REZOLVE-AA study of rezpegaldesleukin. Filing
  11. Mar 12, 2026ResultsReleased financial results. Filing
  12. Feb 13, 2026AgreementNektar Therapeutics entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. as the representatives of the several underwriters named therein, relating to an underwritten offering of (i) 6,603,449 shares of the Company’s common stock, $0.0001 par… Filing
  13. Feb 10, 2026AnnouncementShared information with investors. Filing
  14. Feb 10, 2026AnnouncementThe Company announced results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD study of rezpegaldesleukin. Filing
  15. Jan 27, 2026AnnouncementShared information with investors. Filing
  16. Dec 16, 2025AnnouncementThe Company announced topline results from the 36-week induction treatment period for its Phase 2b REZOLVE-AA (alopecia areata) clinical trial. Filing
  17. Nov 21, 2025LeadershipNektar Therapeutics announced that Mark A. Wilson will step down as Chief Legal Officer of Nektar, effective as of December 31, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Nektar Therapeutics financials

Famous investors that hold NKTR

2 of the 50 well-known investors we track reported holding NKTR in their latest 13F filing. The largest position is Israel Englander's, worth $12.3M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026203,632$12.3M0.0%-57%
Ken Griffin · Citadel AdvisorsQ3 202636,803$2.2M0.0%-77%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NKTR in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G5.2%
Nov 10, 2026STATE STREET CORPORATION13G5.2%

Questions about Nektar Therapeutics (NKTR) stock

Who owns the most NKTR stock?

The largest reported owner of Nektar Therapeutics (NKTR) is FMR LLC (Fidelity), with 17.7% of the company. In total, 239 funds and institutions reported holding NKTR at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are NKTR insiders buying or selling?

In the last 12 months, NKTR insiders reported no open-market purchases and 16 sales worth $2.4M. The latest trade was on Aug 18, 2026. See every trade.

What is the short interest in NKTR?

As of Oct 30, 2026, 6.77M NKTR shares were sold short, 19.8% of the shares outstanding, down 3.3% from the report before. At the average daily volume of 659,707 shares, buying them all back would take about 10.3 trading days (days to cover). See the history.

Which famous investors hold NKTR?

2 of the 50 well-known investors we track reported NKTR in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $12.3M. See all holders.

Executive pay

Nektar Therapeutics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, up 66% from $3.8M the year before. In the last 12 months, Nektar Therapeutics's executives and directors bought no stock on the open market and sold $2.4M.

Chief executive, total pay$6.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$14.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.